Ipinzan

Metformin Hydrochloride / Vildagliptin, the active ingredient in Ipinzan, is a Biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients. It combines complementary mechanisms to improve glycemic control while minimizing the risk of hypoglycemia.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Ipinzan is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

- Type 2 diabetes mellitus: improves overall glycemic control by lowering fasting and post‑prandial glucose levels. - Adjunct to diet and exercise: enhances the effectiveness of lifestyle interventions in patients whose glucose remains uncontrolled. - Combination therapy: provides additional glucose lowering when metformin alone is insufficient.

Ipinzan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Ipinzan, several safety considerations should be evaluated to minimize risks. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: monitor liver enzymes, as metformin is contraindicated in significant hepatic disease. - Cardiovascular status: use caution in patients with congestive heart failure or unstable cardiac conditions. - Age: elderly patients may require dose adjustment and closer monitoring. - Concomitant alcohol: limit intake to reduce risk of lactic acidosis. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Ipinzan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, enhancing toxicity. - Alcohol: excessive consumption heightens the chance of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas: combined use may increase risk of hypoglycemia. - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: can reduce renal perfusion, impacting metformin elimination.